Early research (Phase 1)Study completedNCT00866853
What this trial is testing
TMC435-TiDP16-C107: This Study Measures the (Possible) Influence of TMC435 on the Activity of a Selected Set of Drug-degrading Proteins by Measuring the Blood Levels of Drugs That Have Been Taken Together With TMC435 and That Are Known to be Specifically Degraded by These Drug-degrading Proteins.
Who this might be right for
Hepatitis CViruses
Tibotec Pharmaceuticals, Ireland 16